Cargando...
Targeting KRAS-mutant non-small cell lung cancer: challenges and opportunities
Oncogenic mutations in Kirsten rat sarcoma viral oncogene homolog (KRAS) occur in 15%–30% of non-small cell lung cancer (NSCLC). However, despite decades of intensive research, there is still no direct KRAS inhibitor with clinically proven efficacy. Considering its association with poor treatment re...
Guardado en:
| Publicado en: | Acta Biochim Biophys Sin (Shanghai) |
|---|---|
| Autores principales: | , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Oxford University Press
2016
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4689161/ https://ncbi.nlm.nih.gov/pubmed/26578706 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/abbs/gmv118 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|